CLINICAL_TRIALS trial_result · 2014-05-26

Clinical Trial Update: Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer [Phase 2]

Phase 2 trial evaluating Axitinib (AG-013736) with and without dose titration in patients with renal cell carcinoma; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2014-05-26